Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1890 1
1892 1
1893 1
1894 3
1896 4
1898 1
1899 1
1925 1
1926 1
1928 1
1929 1
1932 2
1933 1
1934 2
1935 2
1936 1
1937 1
1945 3
1946 10
1947 17
1948 18
1949 18
1950 31
1951 37
1952 30
1953 60
1954 52
1955 77
1956 80
1957 69
1958 68
1959 68
1960 76
1961 84
1962 113
1963 172
1964 237
1965 191
1966 207
1967 247
1968 256
1969 274
1970 274
1971 294
1972 280
1973 327
1974 271
1975 288
1976 325
1977 278
1978 252
1979 313
1980 292
1981 295
1982 396
1983 350
1984 434
1985 498
1986 540
1987 663
1988 679
1989 839
1990 933
1991 974
1992 1028
1993 1260
1994 1303
1995 1391
1996 1516
1997 1737
1998 1850
1999 1980
2000 2275
2001 2485
2002 2763
2003 2992
2004 3354
2005 3664
2006 3731
2007 3753
2008 4035
2009 4245
2010 4490
2011 4992
2012 5155
2013 5408
2014 5646
2015 6204
2016 6449
2017 6561
2018 6755
2019 6965
2020 8137
2021 8577
2022 8464
2023 8340
2024 4199

Text availability

Article attribute

Article type

Publication date

Search Results

138,040 results

Results by year

Filters applied: . Clear all
Page 1
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.
Kendler DL, Cosman F, Stad RK, Ferrari S. Kendler DL, et al. Adv Ther. 2022 Jan;39(1):58-74. doi: 10.1007/s12325-021-01936-y. Epub 2021 Nov 11. Adv Ther. 2022. PMID: 34762286 Free PMC article. Review.
Here, we examine these questions through the lens of data from the FREEDOM trial program and other studies to determine where denosumab fits in the osteoporosis treatment landscape. Clinical consensus and evidentiary support have grown for denosumab as a high …
Here, we examine these questions through the lens of data from the FREEDOM trial program and other studies to determine where denosumab …
Denosumab: mechanism of action and clinical outcomes.
Hanley DA, Adachi JD, Bell A, Brown V. Hanley DA, et al. Int J Clin Pract. 2012 Dec;66(12):1139-46. doi: 10.1111/ijcp.12022. Epub 2012 Sep 12. Int J Clin Pract. 2012. PMID: 22967310 Free PMC article. Review.
AIMS: To describe the mechanisms of action of denosumab, a novel antiresorptive agent, contrasting it with other antiresorptive and anabolic osteoporosis treatments. ...Identified by Osteoporosis Canada Clinical Practice Guidelines as a first-line agent for t …
AIMS: To describe the mechanisms of action of denosumab, a novel antiresorptive agent, contrasting it with other antiresorptive and a …
Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y. Kobayakawa T, et al. Sci Rep. 2021 Jun 3;11(1):11801. doi: 10.1038/s41598-021-91248-6. Sci Rep. 2021. PMID: 34083636 Free PMC article.
Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment. ...Romosozumab showed a higher potential for improving BMD than denosumab in this clinical study of pos …
Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal …
Denosumab Discontinuation.
Sølling AS, Tsourdi E, Harsløf T, Langdahl BL. Sølling AS, et al. Curr Osteoporos Rep. 2023 Feb;21(1):95-103. doi: 10.1007/s11914-022-00771-6. Epub 2022 Dec 24. Curr Osteoporos Rep. 2023. PMID: 36564572 Review.
PURPOSE OF REVIEW: To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation. RECENT FINDINGS: Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bo …
PURPOSE OF REVIEW: To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab dis …
Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment.
Tański W, Kosiorowska J, Szymańska-Chabowska A. Tański W, et al. Eur Rev Med Pharmacol Sci. 2021 May;25(9):3557-3566. doi: 10.26355/eurrev_202105_25838. Eur Rev Med Pharmacol Sci. 2021. PMID: 34002830 Free article. Review.
Osteoporosis is a metabolic disease of the skeletal system which currently affects over 200 million patients worldwide. ...Pharmaceutical treatment for osteoporosis involves bisphosphonates, calcium and vitamin D3, denosumab, teriparatide, raloxifene, and str …
Osteoporosis is a metabolic disease of the skeletal system which currently affects over 200 million patients worldwide. ...Pharmaceut …
Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A. Shane E, et al. J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1528-e1540. doi: 10.1210/clinem/dgab850. J Clin Endocrinol Metab. 2022. PMID: 34849989 Free PMC article. Clinical Trial.

Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 7.8% at the LS, 9.8 4.6% at the TH, and 9.5 4.7% at the FN (all P < .0001). ...Serum BTM decreased by 75% to 85% by 3 months and remained suppressed through 12 months of

…
Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 7.8% at the LS, 9.8 4.6% at the …
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Tsourdi E, et al. Bone. 2017 Dec;105:11-17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5. Bone. 2017. PMID: 28789921 Review.
INTRODUCTION: The optimal duration of osteoporosis treatment is controversial. As opposed to bisphosphonates, denosumab does not incorporate into bone matrix and bone turnover is not suppressed after its cessation. ...However, since the optimal bisphosphonate regime …
INTRODUCTION: The optimal duration of osteoporosis treatment is controversial. As opposed to bisphosphonates, denosumab does n …
Stopping Denosumab.
Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Lamy O, et al. Curr Osteoporos Rep. 2019 Feb;17(1):8-15. doi: 10.1007/s11914-019-00502-4. Curr Osteoporos Rep. 2019. PMID: 30659428 Review.
In five recent case series, the median number of vertebral fractures was 5 within 7 to 20 months (median 11) after the last denosumab injection. Prescribing bisphosphonate before starting denosumab and/or after stopping denosumab may reduce this risk. ...A po …
In five recent case series, the median number of vertebral fractures was 5 within 7 to 20 months (median 11) after the last denosumab …
Osteoporosis Management.
Batur P, Rice S, Barrios P, Sikon A. Batur P, et al. J Womens Health (Larchmt). 2017 Aug;26(8):918-921. doi: 10.1089/jwh.2017.6496. Epub 2017 Jul 7. J Womens Health (Larchmt). 2017. PMID: 28686517 Review.
Topics include menopause, sexual dysfunction, breast health, contraception, osteoporosis, and cardiovascular disease. In this clinical update, we selected recent publications relevant to osteoporosis management. We highlight articles on the safety of long-term use o …
Topics include menopause, sexual dysfunction, breast health, contraception, osteoporosis, and cardiovascular disease. In this clinica …
The Clinical Effectiveness of Denosumab (Prolia) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR, Nicolopoulos K, Stringer D, Ma N, Jenal M, Vreugdenburg T. Moshi MR, et al. Calcif Tissue Int. 2023 Jun;112(6):631-646. doi: 10.1007/s00223-023-01078-z. Epub 2023 Apr 5. Calcif Tissue Int. 2023. PMID: 37016189 Review.
To assess the effectiveness and safety of denosumab (Prolia) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in p …
To assess the effectiveness and safety of denosumab (Prolia) compared to bisphosphonates (alendronate, ibandronate, risedronate, zole …
138,040 results
You have reached the last available page of results. Please see the User Guide for more information.